The ANTIPARK project was selected in the ANR Emergence 2010 campaign. BioCIS is the leader of the project by Bruno Figadère with ICM (Paris 6), U930 Inserm (Tours), ICSN (Gif sur Yvette) and FIST (CNRS) as partners. The tasks, performed in the pharmacognosy team and within the partners will contribute to the development of hybrids natural products, which have shown in vitro and in vivo activity on Parkinson disease models. The principal objective is to study a few leads, obtained by screening of an in house focused library on primary cultures of dopaminergic neurons, in in vivo animal models of PD (MPTP lesioned mice and and 6-OH-DA lesioned rats) in order to propose a drug candidate. The use of modern imaging techniques, positon emission tomography (PET) and MALDI-Tof MS imaging will allow us to study the location of the active compounds in the brain of treated animals.
Accueil > Teams > Pharmacognosy - Chemistry of Natural Products > ANTIPARK : New synthetic compounds with neuroprotection and neuritogenesis activities for the treatment of Parkinson disease.
ANTIPARK : New synthetic compounds with neuroprotection and neuritogenesis activities for the treatment of Parkinson disease.
